Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamsulosin versus tamsulosin + mirabegron for ureteral stent symptoms after TUL
IRCT20230409057864N4Phase 3Recruiting
- Sponsor
- Kerman University of Medical Sciences
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of tamsulosin and mirabegron in ureteral stent-related symptoms (USRS), Micturition disorder and pain (2 arms), sponsored by Kerman University of Medical Sciences. Primary endpoints: Mean Ureteral Stent Symptom Questionnaire score, Mean International Prostate Symptom Score and 1 more. Started Nov 2026; status: recruiting.
02
Drugs
tamsulosinmirabegron
03
Conditions
ureteral stent-related symptoms (USRS)Micturition disorderpain
Beyond the preview
Go deeper on IRCT20230409057864N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230409057864N4.